About 98% of all Norwegian patients with testicular cancer are cured. Norway, together with Sweden, have the best survival results in Europe (2).
The prognosis depends on the histology, extent of the disease, localization of metastases, tumor size and level of tumor markers. Patients with extragonadal nonseminoma with mediastinal localization fall into a poor prognostic group. Relapse after previous chemotherapy generally has a poor prognosis. About 25% of the patients live for 5 years (2).
Five percent of patients with testicular cancer will develop new cancer in the contralateral testicle in their lifetime (4).
All patients with metastasizing seminoma have either a good or intermediate prognosis. Seminoma in the good prognosis group has a 5-year survival of 86%, while the intermediary prognosis group has a 72% survival (7).
Nonseminoma in the good prognostic group has a 5-year survival of 92%. In the intermediary prognostic group, 5-year survival is 80%. The poor prognostic group has a 48% of 5-year survival (8).
Five-year relative survival of patients with testicular cancer, in percent, according to stage during the diagnosis period 1974–2013.
Source: Cancer Registry of Norway